MVA-mBN32

BIOLOGICAL3 trials

Sponsors

Bavarian Nordic, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV Infections

Phase 1

Safety and Immunogenicity Study of Recombinant Modified Vaccinia Virus Ankara (MVA) Virus to Treat HIV Infection

CompletedNCT00386633

Bavarian NordicHIV Infections

Start: 2006-10-31End: 2007-11-30Target: 36Updated: 2015-01-27

Single-Blind, Controlled Safety and Immunogenicity Study of Recombinant MVA Virus to Treat HIV Infection

CompletedNCT00390078

Bavarian NordicHIV Infections

Start: 2007-01-31End: 2009-01-31Target: 30Updated: 2009-07-10

Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults

CompletedNCT00428337

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2007-04-30End: 2008-08-31Updated: 2021-10-14

Related Papers

Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic review.

2013-01-1726 citations